Detection of emerging neurodegeneration using Bayesian linear mixed-effect modeling.


Journal

NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070

Informations de publication

Date de publication:
2022
Historique:
received: 04 10 2021
revised: 20 07 2022
accepted: 02 08 2022
pubmed: 29 8 2022
medline: 15 12 2022
entrez: 28 8 2022
Statut: ppublish

Résumé

Early detection of neurodegeneration, and prediction of when neurodegenerative diseases will lead to symptoms, are critical for developing and initiating disease modifying treatments for these disorders. While each neurodegenerative disease has a typical pattern of early changes in the brain, these disorders are heterogeneous, and early manifestations can vary greatly across people. Methods for detecting emerging neurodegeneration in any part of the brain are therefore needed. Prior publications have described the use of Bayesian linear mixed-effects (BLME) modeling for characterizing the trajectory of change across the brain in healthy controls and patients with neurodegenerative disease. Here, we use an extension of such a model to detect emerging neurodegeneration in cognitively healthy individuals at risk for dementia. We use BLME to quantify individualized rates of volume loss across the cerebral cortex from the first two MRIs in each person and then extend the BLME model to predict future values for each voxel. We then compare observed values at subsequent time points with the values that were expected from the initial rates of change and identify voxels that are lower than the expected values, indicating accelerated volume loss and neurodegeneration. We apply the model to longitudinal imaging data from cognitively normal participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI), some of whom subsequently developed dementia, and two cognitively normal cases who developed pathology-proven frontotemporal lobar degeneration (FTLD). These analyses identified regions of accelerated volume loss prior to or accompanying the earliest symptoms, and expanding across the brain over time, in all cases. The changes were detected in regions that are typical for the likely diseases affecting each patient, including medial temporal regions in patients at risk for Alzheimer's disease, and insular, frontal, and/or anterior/inferior temporal regions in patients with likely or proven FTLD. In the cases where detailed histories were available, the first regions identified were consistent with early symptoms. Furthermore, survival analysis in the ADNI cases demonstrated that the rate of spread of accelerated volume loss across the brain was a statistically significant predictor of time to conversion to dementia. This method for detection of neurodegeneration is a potentially promising approach for identifying early changes due to a variety of diseases, without prior assumptions about what regions are most likely to be affected first in an individual.

Identifiants

pubmed: 36030718
pii: S2213-1582(22)00209-1
doi: 10.1016/j.nicl.2022.103144
pmc: PMC9428846
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103144

Subventions

Organisme : NIA NIH HHS
ID : K23 AG061253
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG045333
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062422
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG019724
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG032306
Pays : United States
Organisme : NIA NIH HHS
ID : K08 AG052648
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG045390
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS092089
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG032438
Pays : United States

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yann Cobigo (Y)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States. Electronic address: yann.cobigo@ucsf.edu.

Matthew S Goh (MS)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States.

Amy Wolf (A)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States.

Adam M Staffaroni (AM)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States.

John Kornak (J)

University of California, San Francisco, Department of Epidemiology and Biostatistics, United States.

Bruce L Miller (BL)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States.

Gil D Rabinovici (GD)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States.

William W Seeley (WW)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States.

Salvatore Spina (S)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States.

Adam L Boxer (AL)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States.

Bradley F Boeve (BF)

Mayo Clinic, Rochester, Department of Neurology, United States.

Lei Wang (L)

Northwestern University Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences and Department Radiology, United States.

Ricardo Allegri (R)

FLENI Institute of Neurological Research (Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia), Argentina.

Marty Farlow (M)

Indiana University, United States.

Hiroshi Mori (H)

Osaka City University Medical School, Department of Neurosciences, Japan.

Richard J Perrin (RJ)

Washington University School of Medicine, United States.

Joel Kramer (J)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States.

Howard J Rosen (HJ)

University of California, San Francisco, Department of Neurology, Memory and Aging Center, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH